Hans-Peter Hartung
Voorzitter bij Neuroscience Center, Inc.
Profiel
Hans-Peter Hartung is currently the Chairman of the Neurology Department and a Professor at Heinrich-Heine-Universität Düsseldorf.
He is also the Chairman of Neuroscience Center, Inc., the Director of Multiple Sclerosis International Federation, the Director of European Neurological Society, the Director of International Society of Neuroimmunology, and the Director of European Committee for Treatment & Research in Multiple.
Previously, he served as an Independent Director at Opexa Therapeutics, Inc. from 2014 to 2017.
He obtained his doctorate degree from Heinrich-Heine-Universität Düsseldorf.
Actieve functies van Hans-Peter Hartung
Bedrijven | Functie | Begin |
---|---|---|
Neuroscience Center, Inc.
Neuroscience Center, Inc. Hospital/Nursing ManagementHealth Services Neuroscience Center, Inc. provides hospital services. | Voorzitter | - |
Heinrich-Heine-Universität Düsseldorf | Corporate Officer/Principal | 01-01-2001 |
European Neurological Society
European Neurological Society Miscellaneous Commercial ServicesCommercial Services The European Neurological Society is a professional membership organization. The non-profit company is based in Basel, Switzerland. | Directeur/Bestuurslid | - |
International Society of Neuroimmunology | Directeur/Bestuurslid | - |
European Committee for Treatment & Research in Multiple | Directeur/Bestuurslid | - |
Multiple Sclerosis International Federation
Multiple Sclerosis International Federation Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis International Federation is an international network of over 90 MS organizations. The non-profit company is based in London, UK. The organization provides information on MS in English, Arabic, and Spanish. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Hans-Peter Hartung
Bedrijven | Functie | Einde |
---|---|---|
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Directeur/Bestuurslid | 19-09-2017 |
Opleiding van Hans-Peter Hartung
Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
Multiple Sclerosis International Federation
Multiple Sclerosis International Federation Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis International Federation is an international network of over 90 MS organizations. The non-profit company is based in London, UK. The organization provides information on MS in English, Arabic, and Spanish. | Commercial Services |
European Neurological Society
European Neurological Society Miscellaneous Commercial ServicesCommercial Services The European Neurological Society is a professional membership organization. The non-profit company is based in Basel, Switzerland. | Commercial Services |
Neuroscience Center, Inc.
Neuroscience Center, Inc. Hospital/Nursing ManagementHealth Services Neuroscience Center, Inc. provides hospital services. | Health Services |
International Society of Neuroimmunology | |
European Committee for Treatment & Research in Multiple |